Xyrem

Type: Product

Name: Xyrem

First reported 8 hours ago - Updated 8 hours ago - 1 reports

Jazz Pharmaceuticals Public Limited Company Presents at UBS Global Healthcare Conference, May-21-2013 09:30 AM

Ami Fadia - UBS Investment Bank, Research DivisionGood morning, everybody. Thanks for coming to the UBS Conference. I'm Ami Fadia. I cover mid-cap spec pharma stocks at UBS. It's my pleasure to have Kate, who is the CFO of Jazz Pharmaceuticals, to present. ... [Published Seeking Alpha - 8 hours ago]

Entities: asparaginase, Xyrem, PRIALT

First reported May 21 2013 - Updated May 21 2013 - 1 reports

U.S. v. Caronia: What are the Implications?

This article appeared in Pharmaceutical Compliance Monitor, March 15, 2013, and is reproduced with permission.Alfred Caronia was a pharmaceuticals sales representative for Orphan Medical who, together with a physician in Orphan's speaker program, promoted ... [Published Fish & Richardson - May 21 2013]

Entities: Xyrem, Drugs, United States

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Jazz Pharmaceuticals reports higher Q1 net income, provides outlook for 2013

Jazz Pharmaceuticals plc, a specialty biopharmaceutical company, has reported that net income for the first quarter ended March 31, 2013 was $43.42 million, or $0.71 per diluted share, compared to $27.68 million, or $0.48 per diluted share, for the same ... [Published Individual.com - May 20 2013]

Entities: Jazz Pharmaceuticals Inc, Xyrem, Cash Position

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Select Medical Holdings Corp

3 Value Investing Plays in Health Care

Watch stocks you care aboutThe single, easiest way to keep track of all the stocks that matter...Your own personalized stock watchlist!It's a 100% FREE Motley Fool service...Health care stocks have soared in 2013. Does that mean that there aren't good ... [Published Motley Fool Discussion Boards - May 16 2013]

Entities: Acthar, Select Medical Holdings Corp, Health Care

First reported May 14 2013 - Updated May 14 2013 - 2 reports

Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events

SOURCE Jazz Pharmaceuticals plcDUBLINAn archived version of each audio webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.About Jazz Pharmaceuticals ... [Published WVNS - May 14 2013]

Entities: Jazz Pharmaceuticals Inc, Erwinia Chrysanthemi, Fazaclo, PRIALT, ziconotide

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Jazz shares hit a bad note

Investors in pharmaceuticals businesses are a nervous bunch as Bruce Cozadd and his team at Dublin-based Jazz Pharmaceuticals discovered this week.Despite publishing figures showing a near doubling of revenue following its acquisition of rival Eusa last ... [Published Irish Times - May 10 2013]

Entities: Xyrem, Stocks, Azur Pharma Limited

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Jazz Pharmaceuticals Inc

Potential Xyrem REMS Changes Could Invite Generics

Jazz Pharmaceuticals told investors Monday it expects the FDA to require modifications to the current risk evaluation and mitigation strategy (REMS) for its highly controlled narcolepsy drug Xyrem, a move some analysts say could expand market opportunities ... [Published FDA News - May 09 2013]

Entities: Xyrem, Jazz Pharmaceuticals Inc, Narcolepsy

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Why Jazz Pharmaceuticals Shares Fell Out of Bed

Help yourself with the Fool's FREE and easy new watchlist service today.Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thes ... [Published Motley Fool Discussion Boards - May 08 2013]

Entities: Jazz Pharmaceuticals Inc, Xyrem, Stocks, watchlist

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Jazz Pharmaceuticals plc (JAZZ) Announces First Quarter 2013 Financial Results

Staying up-to-date has never been simpler. Sign up for the today! DUBLIN, May 7, 2013 /PRNewswire/ -- (JAZZ) today announced financial results for the first quarter ended March 31, 2013, updated 2013 financial guidance and key additions to its board of ... [Published BioSpace - May 08 2013]

Entities: Jazz Pharmaceuticals Inc, Xyrem, Dublin

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Jazz Stock Falls As Competitive Fears Shadow Q1 Beat

Posted 12:25 PM ETShares of Jazz Pharmaceuticals (JAZZ) were down 10% in midday trading Wednesday despite a Q1 beat, as investors apparently were spooked by possible generic competition to Jazz's leading drug.On a conference call with analysts late Tuesday, ... [Published Investors Business Daily - May 08 2013]

Entities: Xyrem, Piper Jaffray Companies, Date Rape Drug, Jazz Pharmaceuticals Inc

First reported May 07 2013 - Updated May 08 2013 - 5 reports

Jazz Pharmaceuticals Public Limited Management Discusses Q1 2013 Results - Earnings Call Transcript

Jazz Pharmaceuticals Public Limited (JAZZ) Q1 2013 Earnings Call May 7, 2013 4:30 PM ETOperatorWelcome to the Jazz Pharmaceuticals First Quarter 2013 Earnings Conference Call. Following an introduction from the company, we will open the call to questions. ... [Published Seeking Alpha - May 08 2013]

Entities: Xyrem, PRIALT, Narcolepsy, Jazz Pharmaceuticals Inc

First reported May 02 2013 - Updated May 02 2013 - 2 reports

Analysts: Facebook Concerns Are Unjustified and 2 Other Research Notes to Browse

Facebook ( NASDAQ:FB ): First quarter results tell Cantor that the concerns were unjustified, and believes that the company’s outlook remains strong while its valuation is “relatively compelling.” It keeps a Buy rating on the stock.NEW! Discover a new ... [Published Wall St. Cheat Sheet - May 02 2013]

Entities: Clean Harbors Inc, Facebook Inc, Xyrem, Patent Settlement, Jazz Pharmaceuticals Inc

Quotes

...It declared, unequivocally, that the government "cannot prosecute pharmaceutical manufacturers and their representatives under the FDCA for speech promoting the lawful, off-label use of an FDA-approved drug." Not surprisingly, this decision has been widely hailed as a "victory for freefree speech...

U.S. v. Caronia: What are the Implications? [Published Fish & Richardson - May 21 2013]

...strong top and bottom line growth fueled by growing sales of Xyrem and Erwinaze," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals plc. "We have made substantial progress in the execution of our strategy to maximize the potential of our product portfolio while further strengthening our cash position, positioning us to pursue promising corporate development opportunities and share repurchases."

Jazz Pharmaceuticals reports higher Q1 net income, provides outlook for 2013 [Published Individual.com - May 20 2013]

Jazz's 10-Q filing noted that "the FDA could approve Roxane's ANDA (abbreviated new drug application) with a risk management plan that is separate from our Xyrem deemed REMS, rather than a final REMS or a shared REMS for both the generic and Xyrem."

Jazz Stock Falls As Competitive Fears Shadow Q1 Beat [Published Investors Business Daily - May 08 2013]

...therapies, and their global commitment to patients across multiple therapeutic areas, make them an ideal partner," said Tung in a statement. "We look forward to working with Celgene to evaluate the potential benefits of deuterium-modification for a number of programs emerging in our pipeline."

Celgene turns to Concert for $300M deuterium-tweaking cancer collaboration [Published FierceBiotech - May 06 2013]

More Content

sort by: Date \| Relevance
Jazz Pharmaceuticals Public Limited Company Pre... [Published Seeking Alpha - 8 hours ago]
Now Available: Jazz Pharmaceuticals plc (JAZZ) ... [Published Live-PR.com - 18 hours ago]
U.S. v. Caronia: What are the Implications? [Published Fish & Richardson - May 21 2013]
Jazz Pharmaceuticals reports higher Q1 net inco... [Published Individual.com - May 20 2013]
Jazz Pharmaceuticals plc (JAZZ) - Pharmaceutica... [Published TransWorldNews - May 17 2013]
Hidden Causes of Daytime Sleepiness [Published Bottom Line Publications - May 17 2013]
3 Value Investing Plays in Health Care [Published Motley Fool Discussion Boards - May 16 2013]
Jazz Pharma Posts Higher Y/Y Earnings Zacks [Published Yahoo! Finance - May 14 2013]
Jazz Pharmaceuticals Announces Participation In... [Published SPi World News - May 14 2013]
Jazz Pharmaceuticals Announces Participation In... [Published WVNS - May 14 2013]
Jazz Pharmaceuticals Announces Participation In... [Published FinanzNachrichten.de - May 14 2013]
Jazz shares hit a bad note [Published Irish Times - May 10 2013]
3 Stocks to Buy on Wednesday's Post-Earnings We... [Published Motley Fool - May 09 2013]
Potential Xyrem REMS Changes Could Invite Gene... [Published FDA News - May 09 2013]
Why Jazz Pharmaceuticals Shares Fell Out of Bed [Published Motley Fool Discussion Boards - May 08 2013]
Jazz Pharmaceuticals plc (JAZZ) Announces First... [Published BioSpace - May 08 2013]
Stocks Up In Afternoon; Electronic Arts Hits Ne... [Published Investors Business Daily - May 08 2013]
Jazz Pharmaceuticals plc Announces First Quarte... [Published BioSpace - May 08 2013]
Jazz Stock Falls As Competitive Fears Shadow Q1... [Published Investors Business Daily - May 08 2013]
Jazz Pharma shares slide despite 1Q profit jump [Published INO.com - May 08 2013]
Concert in tune with Celegene for $300 million ... [Published Drug Discovery News - May 08 2013]
Jazz Pharmaceuticals Public Limited Management ... [Published Seeking Alpha - May 08 2013]
Concert Pharma To Get $300M+ Per Drug in Celgen... [Published Oncology Business Review - May 07 2013]
Jazz Pharmaceuticals Guides Higher [Published Earnings Whispers - May 07 2013]
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 20... [Published Bio-Medicine - May 07 2013]
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 20... [Published Barchart - May 07 2013]
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 20... [Published ADVFN UK - May 07 2013]
Celgene turns to Concert for $300M deuterium-tw... [Published FierceBiotech - May 06 2013]
Analysts: Facebook Concerns Are Unjustified and... [Published Wall St. Cheat Sheet - May 02 2013]
Analysts: Facebook Concerns Are Unjustified and... [Published Wall St. Cheat Sheet - May 02 2013]

Blogs

sort by: Date \| Relevance
Analysts: Facebook Concerns Are Unjustified and... [Published Wall St. Cheat Sheet - May 02 2013] Facebook ( NASDAQ:FB ): First quarter results tell Cantor that the concerns were unjustified, and believes that the company’s outlook remains strong while its valuation is “relatively compelling.” It keeps a Buy rating on the stock.NEW! Discover a new ...
Analysts: Facebook Concerns Are Unjustified and... [Published Wall St. Cheat Sheet - May 02 2013] Facebook ( NASDAQ:FB ): First quarter results tell Cantor that the concerns were unjustified, and believes that the company’s outlook remains strong while its valuation is “relatively compelling.” It keeps a Buy rating on the stock. NEW! Discover ...
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Apr 29 2013]
Deals Of The Week: Elan Takes It All Off, Attra... [Published The IN VIVO Blog - Mar 04 2013] Elan Corp. PLC has been engaged in a slow motion strip-tease over the past five years; it has now shed so many assets that it may soon disappear entirely. On Feb. 25, Royalty Pharma fielded an $11/share, $6.5 billion bid for the company . That was ...
Zynga Risk/Reward Seen as Favorable and 4 Stock... [Published Wall St. Cheat Sheet - Feb 27 2013] Cracker Barrel Old Country Store, Inc. ( NASDAQ:CBRL ): Current Price: $73.70 The company’s valuation range was raised by Wells Fargo following the company’s report of Q2 same-store sales above its peer average. The firm thinks that the company’s ...

Press Releases

sort by: Date \| Relevance
Jazz Pharmaceuticals Announces Issuance of Addi... [Published PR Newswire: General Business - Dec 04 2012]
Jazz Pharmaceuticals Announces Issuance of New ... [Published PR Newswire - Sep 11 2012]